AI Innovations Set to Enhance Women’s Cancer Care in Victoria

Researchers in British Columbia are on the brink of a significant advancement in women’s cancer treatment, particularly for endometrial cancer. Dr. Jessica McAlpine and Dr. Ali Bashashati, leading experts at BC Cancer and the University of British Columbia (UBC), have developed an artificial intelligence (AI) system that aims to improve the diagnosis and treatment of this prevalent form of cancer. Endometrial cancer, the sixth most common cancer among women, often presents diagnostic challenges due to the ambiguous appearance of its cells, which can lead to inconsistencies in diagnosis.

The researchers’ work focuses on categorizing endometrial cancer into four distinct groups, each with unique clinical outcomes. Despite this advancement, a significant diversity remained within one of the groups, prompting the introduction of the AI ProMisE test. “We were able to look at these images of tumours and identify things that the pathologist couldn’t see and that the molecular tools couldn’t identify,” McAlpine stated. This breakthrough allows medical professionals to better predict patient outcomes, directing them toward appropriate treatments to prevent recurrences.

Transformative Potential of AI in Cancer Treatment

The use of AI in this context offers numerous benefits. It not only identifies patients who may appear to have favorable prognoses but might actually face worse outcomes, thus facilitating timely interventions. “Because of the tools we now have, some patients can avoid the toxicity of chemotherapy and radiation altogether,” McAlpine added. This capability may reduce unnecessary treatments and mitigate the burden of travel for patients, particularly those in remote communities.

Plans are underway to implement these AI tools in treatment centers, including potential pilot programs in Victoria, possibly starting within the next year. McAlpine expressed optimism about collaborating with local researchers and oncologists, stating, “I think Victoria will be key, and they have a fantastic team of researchers and oncologists that we work with.”

The initiative resonates personally with Dr. Brad Nelson, who recently assumed the role of Immunotherapy Research Chair at BC Cancer in Victoria. His dedication to advancing research in women’s cancers stems from personal connections to the cause, including the loss of Joyce Deeley, a significant BC Cancer benefactor, to ovarian cancer in 2001. The Trev & Joyce Deeley Research Centre was established in her memory following a $5 million donation, underscoring the need for more attention to gynecological cancers.

A Growing Focus on Women’s Cancer Research

William Litchfield, Associate Vice President of the BC Cancer Foundation for Vancouver Island, emphasized the critical nature of this research. “Gynecological cancers are some of the most difficult cancers to treat and historically are an understudied area of cancer research,” he noted. Litchfield highlighted the potential life-saving implications of the innovative work being conducted at BC Cancer, especially for women on Vancouver Island and across British Columbia.

The announcement of these advancements coincides with Gynecological Cancer Awareness Month in September, further highlighting their significance. McAlpine acknowledged that while the application of AI in endometrial cancer treatment is just the beginning, the technology holds promise for further innovations. “There are so many other applications we’re also looking at,” she said, emphasizing the shift towards a more personalized approach in cancer treatment.

As the research progresses, the integration of AI in cancer care could profoundly alter treatment protocols, ensuring women receive the most effective and least invasive options available. With continued support and funding, the future of women’s cancer care in Victoria and beyond looks increasingly promising.